AMLX 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
07 avr. 2024 13h08 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
AMLX 5-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
04 avr. 2024 12h50 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
01 avr. 2024 12h59 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, April 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
AMLX 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Amylyx Pharmaceuticals (AMLX) Investors with Substantial Losses to Contact Firm Before Apr. 9th Deadline in Securities Fraud Class Action
28 mars 2024 15h42 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman
25 mars 2024 14h33 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO® ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
22 mars 2024 09h21 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
18 mars 2024 13h43 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint – Hagens Berman
13 mars 2024 18h50 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, March 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class Period:...
AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline
26 févr. 2024 11h39 HE
|
Johnson Fistel, LLP
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP notifies investors of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) that a securities class action lawsuit...
Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO® Data – Hagens Berman
22 févr. 2024 18h57 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors who suffered substantial losses to submit your losses now. Class...